175 related articles for article (PubMed ID: 31877751)
1. Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.
Lorenzon I; Pellarin I; Pellizzari I; D'Andrea S; Belletti B; Sonego M; Baldassarre G; Schiappacassi M
Cells; 2019 Dec; 9(1):. PubMed ID: 31877751
[TBL] [Abstract][Full Text] [Related]
2. Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.
Sonego M; Pellizzari I; Dall'Acqua A; Pivetta E; Lorenzon I; Benevol S; Bomben R; Spessotto P; Sorio R; Gattei V; Belletti B; Schiappacassi M; Baldassarre G
Sci Rep; 2017 Aug; 7(1):7104. PubMed ID: 28769043
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
4. Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
Gambelli A; Nespolo A; Rampioni Vinciguerra GL; Pivetta E; Pellarin I; Nicoloso MS; Scapin C; Stefanatti L; Segatto I; Favero A; D'Andrea S; Mucignat MT; Bartoletti M; Lucia E; Schiappacassi M; Spessotto P; Canzonieri V; Giorda G; Puglisi F; Vecchione A; Belletti B; Sonego M; Baldassarre G
EMBO Mol Med; 2024 May; 16(5):1162-1192. PubMed ID: 38658801
[TBL] [Abstract][Full Text] [Related]
5. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
[TBL] [Abstract][Full Text] [Related]
6. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
7. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
[TBL] [Abstract][Full Text] [Related]
8. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
Bhatt M; Ivan C; Xie X; Siddik ZH
Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
[TBL] [Abstract][Full Text] [Related]
9. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract][Full Text] [Related]
10. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
Ranzuglia V; Lorenzon I; Pellarin I; Sonego M; Dall'Acqua A; D'Andrea S; Lovisa S; Segatto I; Coan M; Polesel J; Serraino D; Sabatelli P; Spessotto P; Belletti B; Baldassarre G; Schiappacassi M
Oncogene; 2020 Oct; 39(40):6370-6386. PubMed ID: 32848212
[TBL] [Abstract][Full Text] [Related]
11. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
12. TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.
Sonego M; Poletto E; Pivetta E; Nicoloso MS; Pellicani R; Vinciguerra GLR; Citron F; Sorio R; Mongiat M; Baldassarre G
Cells; 2019 Dec; 9(1):. PubMed ID: 31861382
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
15. Exosomes as mediators of platinum resistance in ovarian cancer.
Crow J; Atay S; Banskota S; Artale B; Schmitt S; Godwin AK
Oncotarget; 2017 Feb; 8(7):11917-11936. PubMed ID: 28060758
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
17. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of a short peptide on p53-null SKOV3 ovarian cancer cells.
Huang YS; Wang TX; Lin XM; Wang H; Li RZ; Zeng X; Zhu C; Chen LK; Guo Q; Liu H; Wu XP
Anticancer Drugs; 2019 Nov; 30(10):973-982. PubMed ID: 31503014
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]